Rabia Ozden has joined Akouos as chief development officer. She was most recently the chief medical officer of gene therapy developer Nightstar Therapeutics, which was acquired by Biogen (NASDAQ: [[ticker:BIIB]]) earlier this year for $800 million. Boston-based Akouos is developing gene therapies to address inherited forms of hearing loss.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
